Protalix starts Phase II trial of oral GCD to treat Gaucher disease

Israel-based Protalix BioTherapeutics has started enrolling patients in its Phase IIa clinical trial of oral glucocerebrosidase (GCD), or oral GCD (PRX-112) for treatment of Gaucher disease.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news